These groundbreaking data resulted in the U.S. Food and Drug Administration (FDA) granting accelerated approval to T-DXd for patients with HER2+ cancer who have received 2 or more prior anti-HER2-targeted therapies in the metastatic setting (18). The gene discussed is ERBB2; the disease is cancer.